Drug Profile
Defosbarasertib - AstraZeneca/Pfizer
Alternative Names: AZD 1152 hQPA; AZD-2811; AZD2811 nanoparticleLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca; BIND Therapeutics
- Developer AstraZeneca; Pfizer
- Class Acetamides; Amines; Antineoplastics; Fluorinated hydrocarbons; Fluorobenzenes; Pyrazoles; Quinazolines; Small molecules
- Mechanism of Action Aurora kinase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Small cell lung cancer
- Phase I/II Acute myeloid leukaemia
- Preclinical Diffuse large B cell lymphoma; Non-small cell lung cancer
- Discontinued Solid tumours
Most Recent Events
- 08 Apr 2022 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 08 Apr 2022 Preclinical development for Diffuse large B-cell lymphoma is ongoing in USA (IV)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Diffuse large B cell lymphoma presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)